All In MedTech

Device Trial Radar · NCT07203092

Effects of Transcranial Photobiomodulation in ADHD

Effects of Transcranial Photobiomodulation on Cognition and Brain Metabolism in Adults With ADHD

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Sep 1, 2025

Primary completion

Nov 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Francisco Gonzalez-Lima, PhDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 2, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 44 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

  • Active transcranial photobiomodulationDevice

    Active transcranial photobiomodulation to the forehead targeting prefrontal cortex involves administration of 1064-nm light delivered via laser with a 4 centimeter beam diameter and 250 mW/cm2 power density for 8 minutes per treatment.

  • Sham transcranial photobiomodulationDevice

    Identical procedure as active group, but without 1064-nm light emitted by the device.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Performance on the Continuous Performance TaskTime frame: 1. Pre-Treatment: Baseline (Visit 1). 2. Post-treatment: Two weeks later (Visit 3).
  2. Prefrontal oxygenation (functional near-infrared spectroscopy)Time frame: 1. Pre-Treatment: Baseline (Visit 1). 2. Post-treatment: Two weeks later (Visit 3).
  3. Scores on the Adult ADHD Self-Report Scale (ASRS) questionnaireTime frame: 1. Pre-Treatment: Baseline (Visit 1). 2. Post-treatment: Two weeks later (Visit 3). 3. Follow-up: Four weeks later (Online).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Texas at Austin

    Austin, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.